Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Oral Colchicine (Colcrys®)

In the Treatment and Prophylaxis of Gout

Abstract

Oral colchicine (Colcrys®) is approved in the US for the treatment of acute gout flares in adult patients and the prophylaxis of gout flares in patients aged >16 years.

Colchicine is a tricyclic alkaloid that interrupts multiple inflammatory response pathways. Its principal mechanism of action in gout is thought to be inhibition of cytoskeletal microtubule polymerization, an important process in neutrophil functioning.

In a phase III, randomized, double-blind, placebo-controlled, multicentre trial, the recommended dosage of Colcrys® (1.2 mg at the first sign of the flare, followed by 0.6 mg in 1 hour) was significantly more effective than placebo in treating acute gout flare, as assessed by the proportion of patients experiencing a ≥50% reduction in pain within 24 hours of initiating treatment.

In a randomized, double-blind, placebo-controlled, single-centre trial, non-approved colchicine 0.6 mg once or twice daily (up to 6 months) was more effective than placebo in preventing gout flares in patients receiving allopurinol as urate-lowering therapy.

At the recommended dosage for the treatment of acute gout flares, Colcrys® was as well tolerated as placebo in patients with gout. The incidence of the most common adverse events was similar between recipients of the recommended dosage of Colcrys® and placebo.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Richette P, Bardin T. Gout. Lancet 2010 Jan 23; 375(9711): 318–28

  2. 2.

    Dalbeth N, Haskard DO. Mechanisms of inflammation in gout. Rheumatol 2005 Sep; 44(9): 1090–6

  3. 3.

    Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008 Jul; 10(3): 218–27

  4. 4.

    Schumacher Jr HR, Edwards LN, Perez-Ruiz F, et al. Outcome measures for acute and chronic gout. OMERACT 7 Special Interest Group. J Rheumatol 2005 Dec; 32(12): 2452–5

  5. 5.

    Teng GG, Nair R, Saag KG. Pathophysiology, clinical presentation and treatment of gout. Drugs 2006; 66(12): 1547–63

  6. 6.

    Terkeltaub R, Zelman D, Scavulli J, et al. Gout Study Group: update on hyperuricemia and gout. Joint Bone Spine 2009 Jul; 76(4): 444–6

  7. 7.

    Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009 May; 48 Suppl. 2: ii2–8

  8. 8.

    Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006; 8 Suppl. 1: S2

  9. 9.

    Bhole V, de Vera M, Rahman MM, et al. Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis Rheum 2010 Apr; 62(4): 1069–76

  10. 10.

    Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006 Oct; 65(10): 1312–24

  11. 11.

    Schumacker HR, Taylor W, Edwards L, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009 Oct; 36(10): 2342–5

  12. 12.

    Schlesinger N. Overview of the management of acute gout and the role of adrenocorticotropic hormone. Drugs 2008; 68(4): 407–15

  13. 13.

    Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). Rheumatology (Oxford) 2007 Aug; 46(8): 1372–4

  14. 14.

    Schlesinger N, Schumacher R, Catton M, et al. Colchicine for acute gout. Cochrane Database Syst Rev 2006 Oct 18; (4): CD006190

  15. 15.

    Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 2010 Jun; 48(5): 407–14

  16. 16.

    Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout: a systematic review. Rheumatology (Oxford) 2006 Nov; 45(11): 1422–31

  17. 17.

    Perez-Ruiz F. Treating to target: a strategy to cure gout. Rhuematology (Oxford) 2009 May; 48 Suppl. 2: ii9–14

  18. 18.

    Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010 Jan; 6(1): 30–8

  19. 19.

    Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009 Jun; 38(6): 411–9

  20. 20.

    Bhat A, Naguwa SM, Cheema GS, et al. Colchicine revisited. Ann N Y Acad Sci 2009 Sep; 1173: 766–73

  21. 21.

    Niel E, Scherrmann J-M. Colchicine today. Joint Bone Spine 2006 Dec; 73(6): 672–8

  22. 22.

    Sundy JS. Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 2010 Mar; 22(2): 188–93

  23. 23.

    Mutual Pharmaceutical Company, Inc. Colcrys® (colchicine) oral tablets: US prescribing information [online]. Available from URL: http://www.colcrys.com/assets/pdf/COLCRYS_Full_Prescribing_Information.pdf [Accessed 2010 Jul 2]

  24. 24.

    URL Pharma, Inc. FDA approves Colcrys™ (colchicine, USP) for prevention of gout flares [online]. Available from URL: http://colcrys.com/assets/pdf/Gout%20Prophylaxis%20Press%20Release.pdf [Accessed 2010 Jul 2]

  25. 25.

    US FDA. Rheumatology information: non-selective non-steroidal anti-inflammatory drugs [online]. Available from URL: http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm106979.htm [Accessed 2010 Jul 2]

  26. 26.

    Kesselheim AS, Solomon DH. Incentives for drug development: the curious case of colchicine. N Engl J Med 2010 Jun 3; 362(22): 2045–7

  27. 27.

    Woodcock J. Letter from the US FDA to the American College of Rheumatology [online]. Available from URL: http://www.rheumatology.org/advocacy/colcrys_letter_from_woodcock.pdf [Accessed 2010 Jul 2]

  28. 28.

    Roberts RH. Letter from URL Pharma Inc. to the American College of Rheumatology [online]. Available from URL: http://www.colcrys.com/assets/pdf/Dr%20Roberts%20letter %20to%20Dr%20Cohen.pdf [Accessed 2010 Jul 2]

  29. 29.

    Ravelli RBG, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004 Mar 11; 428(6979): 198–202

  30. 30.

    Pascual E, Castellano JA. Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. J Rheumatol 1992 Apr; 19(4): 600–3

  31. 31.

    Terkeltaub RA, Furst DE, Bennett K, et al. High vs low dosing of oral colchicine for early acute gout flare: twenty-four hour outcome results of the first randomized, placebo-controlled, dose comparison colchicine trial. Arthritis Rheum 2010 Apr; 62(4): 1060–8

  32. 32.

    Chappey ON, Niel E, Wautier J-L, et al. Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther 1993 Oct; 54(4): 360–7

  33. 33.

    Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004 Dec; 31(12): 2429–32

  34. 34.

    Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005 Mar; 52(3): 916–23

  35. 35.

    Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005 Dec 8; 353(23): 2450–61

  36. 36.

    Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010 Apr 6; 12(2): R63

  37. 37.

    Ahern MJ, Reid C, Gordon TP. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987 Jun; 17(3): 301–4

  38. 38.

    AR Scientific, Inc. A multicenter, randomized, double-blind, placebo-controlled, parallel group, 1-week, dose-comparison study to evaluate the efficacy, safety, and tolerability of colchicine in subjects with an acute gout flare. Philadelphia (PA): AR Scientific, Inc., 2008 Sep 23. Report no. MPC-004-06-001

  39. 39.

    Terkeltaub R, Furst DE, Bennett K, et al. Colchicine efficacy assessed by time to 50% reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the AGREE trial [abstract no. 1103]. 73rd Annual Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals; 2009 Oct 16–21; Philadelphia (PA)

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by: F. Perez-Ruiz, Servicio de Reumatología, Hospital de Cruces, Vizcaya, Spain; N. Schlesinger, Division of Rheumatology, Department of Medicine, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; M. Underwood, Warwick Medical School, University of Warwick, Coventry, Warwickshire, England.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Correspondence to Lily P. H. Yang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yang, L.P.H. Oral Colchicine (Colcrys®). Drugs 70, 1603–1613 (2010). https://doi.org/10.2165/11205470-000000000-00000

Download citation

Keywords

  • Colchicine
  • Gout
  • Allopurinol
  • Familial Mediterranean Fever
  • Aprepitant